Takeda inaugurated expanded capacity of solid-dosage drugs at its site in Oranienburg, Germany.
Takeda Pharmaceutical Company has completed the construction of new manufacturing facilities at its site in Oranienburg, Germany, the company announced on June 16, 2017. The new, 21,400-m2 production facility was built at a total cost of around 100 million euros and is scheduled to begin operating at the end of 2017. The state of Brandenburg and the German federal government each contributed half of the approximately 23 million euros in subsidies for the plant expansion.
In a press release issued November 27, 2014, Takeda announced that, as a part of its initiative toward optimization of its global network, the manufacture of solid dosage form pharmaceutical products would be transferred from the Osaka Plant to the Oranienburg Plant and the Hikari Plant. The completion of this new manufacturing facility in Germany is an integral part of this effort.
Specialized in producing solid forms (pills and capsules), the Oranienburg site, which has a 130-year history of pharmaceutical production in Germany, plays a key role in Takeda’s global manufacturing network. Many of Takeda’s drug products are manufactured and supplied to 100 countries worldwide from the Oranienburg site. The expanded production capacity of the Oranienburg site will make it possible to meet the increased demand for Takeda’s products in global markets, including rapidly growing emerging markets, and has already created about 180 new jobs.
Source: Takeda
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.